Lv71
3400 积分 2023-10-26 加入
Targeting neuromuscular junction to treat neuromuscular disorders
18天前
已完结
Inflammaging: The ground for sarcopenia?
20天前
已完结
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
25天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
27天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
27天前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
1个月前
已完结
Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment
1个月前
已完结
Effects of medications on hypoxia‐inducible factor in the retina: A review
1个月前
已完结
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study
1个月前
已完结
皖公网安备34019202002308
